Literature DB >> 18184446

Age-related diurnal effect on D2 receptor binding: a preliminary PET study.

Simon Cervenka1, Christer Halldin, Lars Farde.   

Abstract

Animal research has shown a diurnal variation in dopamine neurotransmission, with a reduced release at night. Variations in biomarkers for the dopamine system over the day have, however, not been investigated in human subjects. In this preliminary PET study, we used the radioligands [11C]raclopride and [11C]FLB 457 to determine dopamine D2-receptor binding in 16 human subjects in the morning and evening on the same day. The average difference between morning and evening examinations did not indicate a diurnal effect on D2 receptor availability. However, when age was taken into account in the analysis, a pattern emerged where individuals in the lower age range showed reduced evening binding while in older subjects binding potential increased. The product-moment correlation between morning-evening change and age was statistically significant in insula, medial frontal cortex and rostral anterior cingulate. The findings, if replicated, have direct relevance for applied PET studies and could also prove relevant with regard to age effects on dopamine-related behaviour such as arousal and cognitive performance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184446     DOI: 10.1017/S1461145707008358

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  8 in total

1.  In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB.

Authors:  Christine DeLorenzo; Jean-Dominique Gallezot; John Gardus; Jie Yang; Beata Planeta; Nabeel Nabulsi; R Todd Ogden; David C Labaree; Yiyun H Huang; J John Mann; Fabrizio Gasparini; Xin Lin; Jonathan A Javitch; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

2.  History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine.

Authors:  Lynn M Oswald; Gary S Wand; Hiroto Kuwabara; Dean F Wong; Shijun Zhu; James R Brasic
Journal:  Psychopharmacology (Berl)       Date:  2014-01-22       Impact factor: 4.530

Review 3.  Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.

Authors:  Christopher J Earley; George R Uhl; Stefan Clemens; Sergi Ferré
Journal:  Sleep Med       Date:  2016-06-27       Impact factor: 3.492

4.  In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.

Authors:  Yumi Oboshi; Yasuomi Ouchi; Shunsuke Yagi; Satoshi Kono; Noriyoshi Nakai; Etsuji Yoshikawa; Masami Futatsubashi; Tatsuhiro Terada; Kang Kim; Kiyoshi Harada
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-11       Impact factor: 6.200

5.  Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.

Authors:  Yoshiteru Takekita; Chiara Fabbri; Masaki Kato; Shinpei Nonen; Shiho Sakai; Naotaka Sunada; Yosuke Koshikawa; Masataka Wakeno; Gaku Okugawa; Toshihiko Kinoshita; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-05-28       Impact factor: 5.270

6.  Increased synaptic dopamine in the putamen in restless legs syndrome.

Authors:  Christopher J Earley; Hiroto Kuwabara; Dean F Wong; Charlene Gamaldo; Rachel E Salas; James R Brašić; Hayden T Ravert; Robert F Dannals; Richard P Allen
Journal:  Sleep       Date:  2013-01-01       Impact factor: 5.849

7.  Potential Effect of Prolonged Sevoflurane Anesthesia on the Kinetics of [11C]Raclopride in Non-human Primates.

Authors:  Ryosuke Arakawa; Lars Farde; Junya Matsumoto; Naoki Kanegawa; Igor Yakushev; Kai-Chun Yang; Akihiro Takano
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

8.  Test-retest reproducibility of [11C]-L-deprenyl-D2 binding to MAO-B in the human brain.

Authors:  Ryosuke Arakawa; Per Stenkrona; Akihiro Takano; Sangram Nag; Rafael S Maior; Christer Halldin
Journal:  EJNMMI Res       Date:  2017-06-20       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.